Evolus, Inc.
corporate_fare Company Profile
Evolus, Inc. (NASDAQ:EOLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for EOLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for EOLS spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- Evolus 10-Q: $41.7M Cash, $120M Undrawn Debt, Accelerated Jeuveau Inventory Build
- Evolus Posts 13% Revenue Growth, Fourth Straight Positive Adjusted EBITDA, Reaffirms 2026 Outlook
- FDA Flags Jeuveau Instagram Post as Misleading, Evolus Shares Drop
- Evolus Delivers 21% Revenue Jump to $83M in Q2, Sharply Narrows Losses
- Evolus Raises 2026 Outlook After Q2 Revenue Jumps 21%
Financial Snapshot
Short Interest & Short Volume
9.38 days to coverFINRA reported short interest of 6,023,009 shares in EOLS as of the October 30, 2026 settlement, a 6.0% decrease from the prior period — about 9.4 days to cover at its recent average daily volume. On November 20, 2026, 55.2% of EOLS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for EOLS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
Universal Shelf Registration Filed · Renewal of Expiring Program
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →